“The production break was due to the usual pharmaceutical gas supplier refused to continue supplying this raw material,” Martínez posted on Twitter, while saying production had been stopped for nine months.
“They did not even accept to sell some quantities, while we were trying to find another supplier,” he explained.
“For such a reason, we had to buy Salbutamol from a European company, for which we had to pay about $4 million several times more than what it costs to produce it in Cuba”, he added.
During this nine-long period, workers were also affected, Martínez stated.
Although we were never given a direct answer as to the supply suspension cause, we learned the producing company moved its headquarters to the United States.
According to medical literature, fluticasone propionate is administered in severe chronic asthma and in the prophylaxis and treatment of allergic rhinitis.
It is indicated to auxiliary anti-asthmatic therapy in its mild, moderate and severe forms, as well as in chronic obstructive pulmonary disease such as chronic bronchitis.